Marked contrast enhancement in grade 4 astrocytoma is associated with the presence of homozygous CDKN2A deletion, although with low sensitivity (80%) and specificity (58%) (Park et al., 2023). This evidence concerns the gene CDKN2A and astrocytoma (excluding glioblastoma).